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Abstract: 
 
Silymarin, also known as milk thistle extract, inhibits hepatitis C virus (HCV) infection and also 
displays antioxidant, anti-inflammatory, and immunomodulatory actions that contribute to its 
hepatoprotective effects. In the current study, we evaluated the hepatoprotective actions of the 
seven major flavonolignans and one flavonoid that comprise silymarin. Activities tested included 
inhibition of: HCV cell culture infection, NS5B polymerase activity, TNF-α-induced NF-κB 
transcription, virus-induced oxidative stress, and T-cell proliferation. All compounds were well 
tolerated by Huh7 human hepatoma cells up to 80 μM, except for isosilybin B, which was toxic 
to cells above 10 μM. Select compounds had stronger hepatoprotective functions than silymarin 
in all assays tested except in T cell proliferation. Pure compounds inhibited JFH-1 NS5B 
polymerase but only at concentrations above 300 μM. Silymarin suppressed TNF-α activation of 
NF-κB dependent transcription, which involved partial inhibition of IκB and RelA/p65 serine 
phosphorylation, and p50 and p65 nuclear translocation, without affecting binding of p50 and 
p65 to DNA. All compounds blocked JFH-1 virus-induced oxidative stress, including 
compounds that lacked antiviral activity. The most potent compounds across multiple assays 
were taxifolin, isosilybin A, silybin A, silybin B, and silibinin, a mixture of silybin A and silybin 
B. The data suggest that silymarin- and silymarin-derived compounds may influence HCV 
disease course in some patients. Studies where standardized silymarin is dosed to identify 
specific clinical endpoints are urgently needed. 
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Article:  
 
Chronic hepatitis C virus (HCV) is a major global medical problem. In the United States, 
millions of people are affected, the number of patients with HCV-induced end-stage liver disease 
is growing (1), and this condition is already the leading indication for liver transplantation (2). 
The current standard of care for chronic hepatitis C, pegylated IFN-α and ribavirin, results in 
sustained elimination of virus in 55% of treated patients (3, 4). However, significant numbers of 
patients do not clear the virus and are intolerant to, have contraindications to, or opt out of 
therapy. Furthermore, because emerging specifically targeted antiviral therapy for HCV therapies 
need to be administered with pegylated IFN plus ribavirin (5), it is likely that many patients will 
not tolerate this therapy. Thus, there are many patients who have no other Food and Drug 
Administration-approved options to eliminate HCV and prevent progression of liver disease. As 
a result, many individuals have opted for complementary and alternative medicine-based 
approaches, including botanicals, to treat their chronic hepatitis C. Indeed, as many as 13 to 23% 
of American patients with chronic liver disease use botanical medicines, with silymarin being the 
most popular (6, 7). 
 
Silymarin, an extract from the seeds of the milk thistle plant, Silybum marianum, has been used 
for centuries as a hepatoprotectant. Although silymarin has been described to possess 
antioxidant, immunomodulatory, antiproliferative, antifibrotic, and antiviral activities (8, 9), its 
mechanisms of action remain to be fully defined. Although its clinical efficacy is currently 
uncertain (8, 10), interest in this botanical medicine has been piqued by studies showing 
silymarin blocks HCV cell culture (HCVcc) infection (9). Intravenous administration of silibinin, 
composed of a 1:1 mixture of silybin A and silybin B, causes dose-dependent reduction of viral 
load in patients with chronic hepatitis C (11). 
 
We previously showed that silymarin blocked HCVcc infection of human hepatoma cultures, 
inhibited TNF-α and TCR induced NFκB-dependent transcription, and suppressed TCR-
mediated proliferation and inflammatory cytokine production from T cells (9, 12). Thus, 
silymarin displays antiviral, anti-inflammatory, and immunomodulatory functions in human liver 
and immune cells. We (13) and others (14) have recently shown that silymarin can also block in 
vitro HCV NS5B polymerase activity at high concentration. Therefore, in the current study, we 
screened the seven major flavonolignans and one flavonoid that comprise silymarin for antiviral, 
antipolymerase, anti-NF-κB, and immunomodulatory actions. In addition, we assessed the 
antioxidant potential of the pure compounds. 
 
Results 
 
Silymarin is a complex of eight major compounds, including seven flavonolignans: silybin A, 
silybin B, isosilybin A, isosilybin B, silychristin, isosilychristin, silydianin, and one flavonoid, 
taxifolin (15). Compounds were purified as previously described (16) (Fig. S1). We then tested 
the effects of silymarin and pure compounds in assays for HCVcc infection, NS5B polymerase 
activity, HCVcc-induced oxidative stress, TNF-α-induced NF-κB transcription, and TCR-
mediated induction of T-cell proliferation. 
 
We first performed cytotoxicity dose-response experiments by measuring ATP levels, a sensitive 
marker of cell viability. All compounds were well tolerated by Huh7.5.1 human hepatoma cells 
up to 80 μM, except for isosilybin B, which was toxic to cells above 10 μM (Fig. S2). Silydianin, 
silychristin, isosilychristin, and taxifolin were not toxic at 100 μM. 
 
Fig. 1A depicts the antiviral effects of the pure compounds against in vitro HCV infection, based 
on HCV protein expression. The concentrations that inhibited HCV protein by 50% (IC50) are 
shown in Table 1. Taxifolin, isosilybin A, and silybin A were the most effective in inhibiting 
JFH-1 infection, and these compounds were more potent than silymarin extract. Silybin B and 
silibinin, a 1:1 mixture of silybin A and silybin B, also inhibited HCV infection with potencies 
similar to silymarin. Isosilychristin, silydianin, and isosilybin B did not inhibit HCV protein 
expression. 
 
 
 
Fig. 1. Antiviral effects of silymarin-derived flavonolignans. (A) Effects on HCV protein 
expression. JFH-1 virus at a multiplicity of infection of 0.05 was adsorbed to Huh7.5.1 cells for 5 
h. After the inoculum was removed, fresh medium was added containing DMSO or 20.7, 41.4, 
82.8, or 124.2 μM of pure flavonolignan (mw 482), or 32.9, 65.8, 131.6, or 197.4 μM of taxifolin 
(mw 304). Protein lysates were harvested 72 h later and HCV protein expression detected by 
Western blot analysis. Actin served as a loading control. (B) Effects on HCV RNA. JFH-1 virus 
at a multiplicity of infection of 0.05 was adsorbed to Huh7.5.1 cells for 5 h. After the inoculum 
was removed, fresh medium was added containing DMSO or pure flavonolignan or taxifolin at 
the concentrations listed above. Total RNA was harvested 72 h later and HCV RNA expression 
quantitified by real-time RT-PCR. The y axis presents the number of copies of HCV RNA per 10 
ng of total RNA. Silydianin (SD), silychristin (SC), isosilychristin (ISC), silybin A (SA), and 
silybin B (SB), taxifolin (TAX), isosilybin A (ISA), isosilybin B (ISB), silibinin (SbN), and 
silymarin (SM). 
 
 
 
Table 1. Hepatoprotective effects of silymarin-derived flavonolignans 
 
Fig. 1B and Table 1 summarize inhibition of HCV RNA replication among the different 
compounds. Taxifolin was the most potent at blocking HCV RNA replication, followed by 
isosilybin A, silybin B, silybin A, silibinin, and silychristin, which were all more potent than 
silymarin. Silydianin and isosilychristin were inactive. 
 
Silymarin inhibits HCV NS5B polymerase activity, albeit at concentrations 5- to 10-fold higher 
than required for HCVcc inhibition (13). We therefore tested the pure compounds for their 
ability to inhibit JFH-1 NS5B polymerase activity. NS5B polymerase inhibition was only 
observed at very high concentrations, with silymarin and silybin B displaying the most potent 
activities, with IC50 values of 300 to 600 μM (Table 1). 
 
In summary, the data indicate that certain silymarin-derived pure flavonolignans can inhibit 
HCV infection as measured by blockade of HCV protein and RNA expression, but that inhibition 
of NS5B RdRp activity can only partly explain the antiviral activity. Indeed, we have shown that 
silymarin blocks virus entry and fusion, and virus production (13). 
 
To determine if silymarin contains antioxidant functions in the context of HCV infection, we 
treated infected cells with silymarin, then labeled cells with the oxidant reactive dye, H2DCFDA, 
and measured fluorescence by microscopy. JFH-1 infection of Huh7.5.1 cells caused large 
increases in fluorescently labeled cells compared with mock-infected cells, indicative of 
oxidative stress (Fig. 2A). Treatment of cells with three different preparations of silymarin (MK-
001, USP, and Legalon) caused significant reductions of cellular fluorescence (Fig. S3). 
Treatment with all eight pure compounds inhibited JFH-1-induced oxidative stress (Fig. 2B). 
IFN, a known antiviral for HCV, also inhibited JFH-1-induced oxidative stress. Silibinin (a 1:1 
mixture of silybin A and silybin B), taxifolin, and isosilybin A had antioxidant activity equal to 
or greater than silymarin, causing greater than 90% reduction in JFH-1-induced oxidative stress. 
Compounds that lacked antiviral action, such as silydianin and isosilychristin, still possessed 
antioxidant function. 
 
 
 
Fig. 2. Silymarin and silymarin-derived flavonolignans block HCV induced oxidative stress. (A) 
Huh7.5.1 cells were infected or mock-infected with JFH-1 at a multiplicity of infection of 0.01 
and 72 h later, cells were labeled with the dye H2DCFDA for 30 min using the Image-IT Live 
Green Reactive Oxygen Species kit (Molecular Probes/Invitrogen). On oxidation, H2DCFDA 
becomes highly fluorescent. Images were captured on a Nikon Microscope using MetaMorph 
software. (B) Huh7.5.1 cells were treated as described above except in addition to silymarin 
(SM), cells were also treated with 41.4 μM of each flavonolignan, 65.8 μM of taxifolin, or 100 
U/mL of IFN-α. ROS were quantitated by pixel intensity. Abbreviations of compounds are listed 
in the legend to Fig. 1. 
 
NF-κB is the key transcription factor that is central to the induction of an inflammatory response 
(17). NF-κB transcription factors are homo- and heterodimeric complexes of proteins with 
molecular weights of 50 and 65 kDa (18). Inactive NF-κB is found in the cytoplasm via its 
association with inhibitory proteins of the IκB family. Stimulation of NF-κB activity involves 
phosphorylation of IκB-α on serine amino acid 32, phosphorylation of NF-κB on serine 536, 
followed by degradation of IκB-α, permitting NF-κB translocation to the nucleus and expression 
of inflammatory response genes (19, 20). 
 
Silymarin blocks NF-κB-dependent transcription from a canonical NF-κB promoter (9). 
Silymarin also blocked TNF-α activation of NF-κB dependent transcription from the positive 
regulatory domain (pRDII) domain of the IFN-B promoter, a key gene in antiviral defense (21) 
(Fig. S4A). Silymarin reduced both p65 and IκB-α serine phosphorylation by about 20% and 
caused an approximate 20% decrease in TNF-α induced p50 and p65 nuclear translocation (Fig. 
S4 C and D). However, silymarin did not affect the ability of p50 or p65 to bind to the NF-κB 
promoter (Fig. S4E). The data suggest that silymarin partially inhibits phosphorylation of IκB-α 
and p65/RelA and nuclear translocation of p50 and p65 subunits of NF-κB, but does not impair 
the ability of NF-κB to bind to DNA. 
 
Fig. 3 depicts examples of the effects on the pure compounds’ abilities to block TNF-α induced 
NF-κB-dependent transcription. In this assay, we were able to test higher concentrations of 
silymarin because the flavonolignans were only incubated with cells for 4 h. Silybin A and 
silybin B caused dose-dependent blockade of TNF-α induced NF-κB dependent transcription, 
with IC50s of 40 μM (Fig. 3 A and B and Table 1). Compared with silybin A and B, taxifolin 
induced the most-pronounced inhibition of NF-κB transcription at the lowest doses, but its effect 
appeared to plateau (Fig. 3C). 
 
 
 
Fig. 3. Silymarin flavonolignans inhibit NF-κB transcription. (A and B) Silybin A and silybin B 
inhibit NF-κB transcription. Huh7 cells were transfected with a luciferase reporter gene under 
control of the pRDII domain from the IFN-B promoter and 24 h later, cells were treated with the 
indicated micromolar doses of each flavonolignan or DMSO control for 30 min before addition 
of 10 ng/mL TNF-α. Luciferase activity was measured 3.5 h later. Error bars represent SDs. (C) 
Comparison of NF-κB inhibitory profiles of silybin A, silybin B, taxifolin, and silychristin. 
 
Table 1 summarizes the effects of silymarin at 40 μM on T-cell proliferation induced by CD3 
ligation. Silymarin, silibinin, silybin A, and isosilybin A displayed the most potent suppression 
of T-cell proliferation. Isosilychristin, silydianin, and taxifolin were essentially inactive. 
Isosilybin B also blocked T-cell proliferation, but this was because of toxicity. In contrast to the 
other measures of hepatoprotection, where some pure compounds were more active than 
silymarin, silymarin was the most potent in blocking T-cell proliferation. Silymarin and pure 
compounds also inhibited inflammatory cytokine expression from T cells (Fig. S5). 
 
Discussion 
 
To our knowledge, this report is unique in characterizing silymarin and silymarin-derived pure 
compounds in four different measures of hepatoprotection in human cells and in the context of 
hepatitis C virus infection. The natural compounds inhibit virus infection, virus-induced 
oxidative stress, NF-κB-dependent transcription, and TCR mediated proliferation. Table S1 
summarizes the data of compound activity in the five hepatoprotective assays. Isosilybin A, 
taxifolin, and silibinin were the most effective hepatoprotectors because they displayed potent 
activity in four of five assays, followed by silybin A and silybin B, which were active in three of 
five assays. Taxifolin was particularly noteworthy because hepatoprotection was observable at 
lower doses than the other compounds, and tended to plateau after reaching a nadir at low doses. 
In contrast, the other compounds showed more linear dose-response relationships. Intriguingly, 
all compounds inhibited virus-induced oxidative stress regardless of whether they had antiviral 
activity. 
 
With the exception of T cell proliferation, several purified compounds were more potent than the 
parent silymarin extract. Although some complementary and alternative medicine practioners 
may emphasize that it is the combination of bioactive molecules in a botanical extract that 
defines its unique biological properties, our data suggest that combinations of flavonolignans 
may provide optimal hepatoprotection. Because the structures of the flavonolignan stereoisomers 
are similar, there may be competitive interactions between flavonolignans for cellular targets. 
This possibility implies that the hepatoprotective potential of select mixtures of pure compounds 
could in theory be greater than the silymarin extract itself. Moreover, different combinations of 
flavonolignans might be selected, depending on the hepatoprotective functions one is targeting. 
Given that isosilybin B is very toxic in cell culture, as shown here, select combinations may be 
especially relevant if one is trying to minimize cytotoxicity for treatment of liver diseases of both 
viral and nonviral origin. Further studies that examine combinations and define the cellular 
targets of the pure compounds are needed to resolve these issues. 
 
In the current study, although silymarin and silybin B appeared to be the most potent polymerase 
inhibitors, the IC50 concentrations were much higher than the concentrations that caused 
cytotoxicity. Moreover, silymarin displays weak polymerase inhibition against four clinical 
isolates of genotype 1b HCV RdRps, and silymarin does not inhibit HCV replication in 
noninfectious replicon cell lines (13). Therefore, we propose that polymerase inhibition by the 
natural compounds, although demonstrable in vitro, may not contribute to anti-HCVcc action in 
vitro, and plays a limited role in antiviral effects in patients with chronic hepatitis C when 
silymarin is taken orally. However, the i.v. formulation of silibinin that displays antiviral effects, 
Legalon-SIL, is actually the dihydrogen disuccinate disodium versions of silybin A and silybin 
B. This chemical modification makes silibinin water soluble, so this formulation may have a 
different antiviral profile and mechanism of action than the natural compounds. 
 
NF-κB serine phosphorylation is required for maximal transcriptional activation by NF-κB (22). 
We showed that silymarin partially inhibits NF-κB-dependent transcription via partial blockade 
of phosphorylation of Ser536 on the p65 subunit of NF-κB and serine32 on IκB-α. Silymarin 
also partially inhibited nuclear translocation of the p50 and p65 NF-κB subunits. These results 
are in agreement with previous studies in prostate cancer cells, where silibinin was shown to 
block p50/p65 nuclear translocation and IKK-α activity (23). 
 
HCV infection induces oxidative stress and inflammation (24–27). Unchecked oxidative stress 
can modify proteins and lipids, damage DNA, alter mitochondrial membrane potential, and be a 
predisposing event in the progression of liver disease. In the present study, we demonstrated that 
JFH-1 infection caused large increases in oxidative stress. These effects were abrogated by 
silymarin and pure compound treatment. We suggest that silymarin inhibits HCV-induced 
oxidative stress by at least two mechanisms. First, silymarin's demonstrated antiviral actions 
could have reduced HCV replication and the ensuing oxidative stress. Second, flavonolignan 
components of silymarin may have direct antioxidant functions without antiviral functions. 
Evidence in support of both modes of action was provided in the present study. These data 
extend silymarin's previously documented antioxidant functions (28) to the context of HCV 
infection. Because silymarin inhibits oxidative stress independently of suppression of virus, it is 
possible that the hepatoprotective actions of the botanical may be extended to liver diseases of 
nonviral origin. 
 
Although silibinin, which is a mixture of silybin A and silybin B, has been largely touted to 
contain many of the hepatoprotective functions (28, 29), we are unique in showing that there are 
other flavonolignans in silymarin that are equal to, if not more potent, than silibinin. The best 
examples are isosilybin A and taxifolin, which have antiviral activities that were superior to 
silibinin. Yet in T cell proliferation silibinin, but not taxifolin, displayed significant activity. 
These data underscore the importance of careful evaluation of all flavonolignans and that the 
activity of each flavonolignan may vary depending on the biological assay. 
 
Our data suggest that silymarin and silymarin-derived compounds could influence HCV disease 
course in some persons. Although standardized silymarin has an exceptional safety record (8), 
the effects observed in vitro occur at relatively high concentrations, so additional studies are 
necessary to assess if adverse effects occur in humans at these levels. Therefore, we caution 
against the self-administration of large amounts of these botanicals, particularly those purchased 
as dietary supplements, because there is inconsistency in the standardization of these products, 
the entire contents may not be known, they may contain contaminants, and misuse of herbals can 
cause hepatotoxicity (30). On the other hand, the activities observed in the present study using 
highly pure natural compounds suggests great promise for the treatment of hepatitis C, for which 
previously unexplored therapeutics are urgently needed. 
 
Silymarin is an interesting botanical extract that has a multitude of biological activities. The four 
activities we measured: antiviral, antioxidant, anti-inflammatory, and immunomodulatory, are all 
likely to be directly related to its well-described hepatoprotective actions (31), but seemingly 
much harder to demonstrate in humans (32). Although the latter may be primarily because of the 
metabolism and bioavailability of silymarin and a dearth of properly designed clinical studies, it 
is clear that further studies are necessary to define the molecular mechanisms by which silymarin 
exerts such pleiotropic effects. 
 
Methods 
 
Subjects. Subjects with and without chronic HCV infection were recruited at Harborview 
Medical Center after written informed consent was obtained through a University of Washington 
Institutional Review Board–approved protocol. 
 
PBMC Isolation and Proliferation Assay. Peripheral blood mononuclear cells (PBMCs) were 
isolated within 24 h of venipuncture and immediately assayed. PBMC were stimulated for 24 h 
at 37 °C 5% CO2 using plate-bound anti-CD3 (UCHT1, 10 μg/mL, BD Biosciences) in RPMI 
medium 1640 supplemented with 10% human serum (Gemini Bio-Products). Cellular 
proliferation detected by 3H-thymidine incorporation into replicating DNA was measured by 
adding 1 μCi to each replicate well of 105 PBMC for an additional 24 h before quantitative 
analysis using a Topcount Liquid Scintillation Counter (Perkin-Elmer). All experiments used 
four replicates per condition. Data were obtained as mean cpm incorporated per condition tested. 
Percent inhibition was calculated using the following formula: 100 × (vehicle-treated mean cpm 
− compound-treated mean cpm)/vehicle-treated mean cpm. 
 
Cells, Virus, and Plasmids. Huh7.5.1 cells were grown in Huh7 medium as described (9). JFH-
1 viral stock preparation, cell infection, and titration was performed as described (33–35). For 
antiviral assays, cells were in infected at a multiplicity of infection of 0.05 and protein and RNA 
harvested 72 h postinfection. To measure NF-κB–dependent transcription, we used a luciferase 
reporter gene under control of the positive regulatory domain (pRDII), which contains the NF-κB 
site from the IFN-B promoter. 
 
Silymarin Preparations, and Pure Compounds. Three preparations of silymarin were used in 
the current study. The first was MK-001, prepared as described (9, 36). The second preparation 
was commercially prepared (Legalon; Madaus). The third preparation was purchased from US 
Pharmacopeia. Silymarin was solubilized in DMSO at 50 mg/mL for Huh7 cell studies; methanol 
was the solvent for PBMC studies. Pure flavonolignans were solubilized at 50 mg/mL in DMSO 
for all studies except PBMC studies, where methanol was used as the solvent. 
 
Silymarin treatment of Huh7.5.1 cultures consisted of adding silymarin immediately after 
removing the viral inoculum. For PBMC studies, silymarin or pure compounds were added to 
cells at the same time that they were exposed to plate-bound anti-CD3 (T-cell receptor antibody). 
 
Cytotoxicity Determinations. The toxicity of silymarin extracts and pure flavonolignans on 
Huh7.5.1 cells was determined by measuring ATP levels using the ATPlite system (Perkin-
Elmer), as described (9). 
 
Reporter Gene Assays. Reporter gene assays were performed as described (37). Endotoxin free 
plasmid DNA was purified (Endofree kit, Qiagen), and was introduced into cells with 
Lipofectamine 2000 according to manufacturer's recommendations (Invitrogen). Next, 100 ng of 
the pRDII-luciferase gene was transfected into cells in quadruplicate. Eighteen hours later, cells 
were preincubated with silymarin or pure compounds for 30 min before rhTNF-α (15 ng/mL; 
Sigma Aldrich) was added. Four hours later, luciferase activity was measured on cell lysates 
using the Britelite Assay System (Perkin-Elmer). 
 
Western Blot Analysis. NS5A and core proteins in JFH-1 infected cells were detected with 
serum from patients infected with HCV genotype 2a. The HCV core protein was detected with a 
monoclonal antibody (Affinity BioReagents). GAPDH was detected with polyclonal antiserum 
(Santa Cruz Biotechnology). NF-κB antibodies consisted of a monoclonal antibody to RelA/p65 
Serine 536, IκBα Serine 32 (Cell Signaling), and antibodies to p50 and p65 subunits 
(Upstate/Millipore). For Western hybridizations and washings, both the standard seal a meal bag 
approach and the Snap-ID system (Millipore) were used. 
 
Oxidative Stress Measurements. Huh7.5.1 cells were incubated with 20 μg/mL of silymarin or 
pure flavonlignans immediately after virus adsorption. Seventy-two hours later, cells were 
labeled with the dye 2',7'-dichlorodihydrofluorecein diacetate (H2DCFDA) for 30 min using the 
Image-IT Live Green Reactive Oxygen Species kit (Molecular Probes/Invitrogen). H2DCFDA is 
a cell-permeable indicator for reactive oxygen species that is nonfluorescent until the acetate 
groups are removed by intracellular esterases and oxidation occurs within the cell. On oxidation, 
H2DCFDA becomes highly fluorescent Pharmacopeia. Images were captured on a Nikon 
Microscope using MetaMorph software (Molecular Devices) with a 20× objective. 
 
HCV NS5B Polymerase Assays. NS5BΔC21 C-terminally fused to a hexa-histidine tag was 
expressed and purified for HCV JFH1 and for the genotype 1b isolates as described (38). JFH-1 
RNA dependent RNA polymerase (RdRp) assays contained buffer, 5 μCi of [α- 32P]GTP, 50 μM 
GTP, 1 mM each ATP, CTP, UTP, 2 μg polyC (GE Healthcare), 1 μg purified polymerase, and 
given amounts of purified compounds in DMSO in a total volume of 25 μL. All reaction 
components except nucleotides and template were preincubated for 15 min at room temperature; 
the reaction was started by adding the nucleotide mixture and polyC and was incubated for 1.5 h 
at room temperature. Reaction products were precipitated, passed through microfilters (GE 
Healthcare), washed five times with 1% trichloroacetic acid and 0.1% tetra-sodium 
pyrophosphate, and air-dried. After addition of 6 mL of Ultima Gold (Perkin-Elmer), samples 
were subjected to liquid scintillation counting. All measurements were performed in triplicate 
and the IC50 values were calculated with GraphPad Prism. 
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Fig. S1. HPLC chromatograms of milk thistle extract (silymarin), the 1:1 mixture of silybin 
A:silybin B (silibinin), the flavonoid (taxifolin), and the seven flavonolignan 
diastereoisomers (silybin A, silybin B, isosilybin A, isosilybin B, silychristin, isosilychristin, and 
silydianin). The structures for all of the pure compounds 
are also shown. 
 
 
 
Fig. S2. Cytotoxicity profiles of silymarin flavonolignans. Huh7 cells were incubated with the 
indicated micromolar concentrations of pure compounds or DMSO and 96 h later, cell viability 
was assessed by measuring ATP levels, expressed as relative light units. Error bars represent SDs 
of triplicate cultures. (A) Profiles of noncytotoxic compounds including silydianin (SD), 
silychristin (SC), isosilychristin (ISC), and taxifolin (TAX). (B) Profiles of compounds that show 
cytotoxicity at high dose including silybin A (SA), and silybin B (SB), isosilybin A (ISA), 
isosilybin B (ISB), silibinin (SbN), and silymarin (SM). ISB is toxic above 10 μM. 
 
 
 
Fig. S3. Silymarin preparations block Hepatitis C virus (HCV)-induced oxidative stress. 
Huh7.5.1 cells were incubated with 41.4 μM of various preparations of silymarin: MK-001, US 
Pharmacopeia, or Legalon (Madaus) immediately after HCV infection. Cells were separately 
treated with DMSO or ethanol as solvent controls. Seventy-two hours later, cells were labeled 
with the dye H2DCFDA for 30 min using the Image-IT Live Green Reactive Oxygen Species kit 
(Molecular Probes/Invitrogen), and images captured by fluorescence microscopy. 
 
 
 
Fig. S4. Effects of silymarin (SM) on NF-κB. (A) SM blocks NF-κB transcription from pRDII. 
Huh7 cells were transfected with a luciferase reporter gene under control of the pRDII domain 
from the IFN-B promoter, and 24 h later cells were treated with the indicated doses of silymarin 
or DMSO control for 30 min before addition of 10 ng/mL TNF-α. Luciferase activity was 
measured 3.5 h later. Error bars represent SDs. (B) SM blocks TNF-induced IkB and NF-κB 
phopshorylation. Huh7 cells were treated for 30 min with DMSO (D) or 41.4 μM silymarin 
before stimulation with 10 ng/mL TNF-α for 15 min. Protein lysates were run on SDS/ PAGE 
gels and probed for phosphorylated forms of NF-κB (Ser536) and IκB (Ser-32). GAPDH was 
probed as a loading control. (C) SM blocks NF-κB Ser536 phosphorylation in human hepatoma 
cells, and has modest reduction in p65 and p50 nuclear translocation. Huh7 cells were treated for 
30 min with DMSO or 41.4 μM SM before stimulation with 10 ng/mL TNF-α for 15 min. 
Cytoplasmic and nuclear extracts were prepared and total forms of p65 and p50 NF-κB subunits 
as well as Ser536 p65 were detected by Western blot. Actin served as a loading control; Stat3 
served as a control for a cytoplasmic protein. (D) SM partially blocks p50 and p65 nuclear 
translocation. Huh7 cells were treated for 30 min with DMSO or 41.4 μM SM before stimulation 
with or without 10 ng/mL TNF-α for 20 min. Cells were fixed and immunofluorescent detection 
of p50 and p65 NF-κB subunits was performed. Nuclei were counterstained with propidium 
iodide (PI). Images were visualized by confocal microscopy. (E) SM does not block binding of 
p50 and p65 to the NF-κB promoter. Huh7 cells were treated for 30 min with DMSO or 41.4 μM 
SM before stimulation with or without 10 ng/mL TNF-α for 20 min. Nuclear extracts were added 
to ELISA plates containing oligonucleotides containing WT NF-κB binding sites, followed by 
detection of p50 and p65 subunits with secondary antibodies. Negative and positive controls 
(−ctrl, +ctrl; Leftmost bars) for p50 and p65 were included in the commercial kit. Specificity was 
demonstrated by adding excess free WT competitor to the reaction (Rightmost bars). 
 
 
 
Fig. S5. PBMC proinflammatory cytokine production is inhibited by purified silymarin 
components. For all assays, a single dose of silymarin and pure compounds or vehicle control 
(methanol; MetOH) was added at culture initiation at 20 μg/mL (41.4 μM for flavonolignans and 
65.8 μM for taxifolin). Freshly isolated PBMC from a healthy subject were tested in triplicate for 
cytokine responses to plate-bound anti-CD3 (10 μg/mL) stimulation. Supernatants collected 24 h 
after anti-CD3 stimulation were tested in triplicate by ELISA for IFN-γ, TNF-α, and IL-2 levels 
by multiplex immunobead ELISA (Biosource/Invitrogen) and the Luminex xMAP system 
(Luminex Corp.). Error bars indicate 1 SD among replicates for each condition. Dashed lines 
indicate the level of inhibition of cytokine secretion by silymarin, for comparison with the 
activity of other subcomponents. 
 
 
